Fetzima (levomilnacipran) costs between $600 and $700 per month at retail price because it is still a brand-name drug with no generic version available on pharmacy shelves. That price tag is roughly 60 times more than what you’d pay for older antidepressants in the same drug class that already have generics. The high cost comes down to patent protection, a lack of market competition, and the economics of branded pharmaceuticals in the United States.
No Generic Competition Yet
The single biggest reason Fetzima costs so much is that no generic alternative is currently being sold. When a drug has patent protection, the manufacturer has exclusive rights to produce and price it. Generic competition is what drives drug prices down dramatically, and Fetzima hasn’t reached that point yet.
The FDA actually approved a generic version of levomilnacipran extended-release capsules back in February 2019. However, approval doesn’t mean a generic can launch immediately. Fetzima is protected by multiple patents listed in the FDA’s Orange Book, and at least two of those patents don’t expire until 2031 and 2032. One patent expired in June 2023, but the remaining ones keep generic manufacturers from bringing their products to market. Until those later patents expire or are successfully challenged, the brand-name version faces no price competition.
How Fetzima Compares to Other SNRIs
Fetzima belongs to a class of antidepressants called SNRIs, which work by increasing levels of two brain chemicals involved in mood regulation. Two other well-known SNRIs, duloxetine (originally sold as Cymbalta) and venlafaxine (originally Effexor), have been available as generics for years. The price difference is staggering.
A 30-day supply of generic duloxetine costs roughly $9 to $12 without insurance. Generic venlafaxine is similarly affordable. Compare that to Fetzima’s list price of approximately $695 per month, and you’re looking at a cost difference of more than 5,000%. This is a pattern seen across the pharmaceutical industry: once generics enter the market, prices collapse. Before that happens, brand-name drugs occupy a pricing tier that reflects R&D costs, marketing budgets, and the manufacturer’s window of exclusivity.
Fetzima does differ from duloxetine and venlafaxine in its chemical makeup. It acts more selectively on one of those two brain chemicals (norepinephrine), which some prescribers believe makes it a better fit for certain patients, particularly those dealing with fatigue or low motivation alongside depression. That pharmacological distinction is part of why some doctors prescribe it despite the cost, but it doesn’t change the fact that the price premium exists because of patent exclusivity, not manufacturing expense.
The Role of Insurance Coverage
Your actual out-of-pocket cost depends heavily on your insurance plan. Many insurers place Fetzima on a high formulary tier, meaning you’ll face a larger copay or coinsurance percentage than you would for a preferred generic SNRI. Some plans require prior authorization, where your doctor must explain why cheaper alternatives aren’t appropriate before the insurer will cover Fetzima at all. Others may not cover it at all, leaving you responsible for the full retail price.
This is a common insurance strategy called step therapy. Plans want you to try less expensive medications first. If duloxetine or venlafaxine didn’t work for you, or caused intolerable side effects, your doctor can document that and request coverage for Fetzima. The process can be frustrating and slow, but it sometimes results in better coverage.
Ways to Lower the Cost
AbbVie, the company that markets Fetzima, offers a patient assistance program called myAbbVie Assist for people who have limited or no insurance coverage. Eligibility is based on household size and income. A single person earning $63,840 or less per year qualifies. For a household of two, the threshold is $86,560. A family of three can earn up to $109,280, and a household of four up to $132,000. If you have insurance, the program reviews your financial need based on a combination of your coverage, income, and out-of-pocket medical expenses.
One important restriction: if your insurance plan requires you to apply to the manufacturer’s assistance program as a condition of coverage (sometimes called an alternate funding program), you’re not eligible for myAbbVie Assist. This is worth knowing because some commercial plans have started routing patients through these programs to shift costs to the drugmaker.
Beyond the manufacturer’s program, prescription discount cards from services like GoodRx or RxAssist can sometimes reduce the price, though the savings on expensive brand-name drugs tend to be more modest than what you’d see with generics. Specialty pharmacies and mail-order services occasionally offer lower pricing as well.
When Prices Could Drop
The key dates to watch are 2031 and 2032, when Fetzima’s remaining patents expire. Once those protections lapse, generic manufacturers who already hold FDA approval will be free to launch their products. Based on how generic entry has worked for other SNRIs, prices could fall to a fraction of the current cost within months of the first generic reaching pharmacies. Until then, Fetzima will remain one of the more expensive options in its class.